Lansforsakringar Fondforvaltning AB publ Has $73.72 Million Holdings in Pfizer Inc. $PFE

Lansforsakringar Fondforvaltning AB publ lessened its position in shares of Pfizer Inc. (NYSE:PFE) by 12.8% in the third quarter, according to its most recent filing with the SEC. The firm owned 2,893,108 shares of the biopharmaceutical company’s stock after selling 426,228 shares during the quarter. Lansforsakringar Fondforvaltning AB publ owned approximately 0.05% of Pfizer worth $73,716,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Norges Bank acquired a new stake in Pfizer in the 2nd quarter valued at $2,270,157,000. Vanguard Group Inc. grew its stake in Pfizer by 1.9% in the 2nd quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock valued at $12,928,730,000 after purchasing an additional 10,198,330 shares during the period. Arrowstreet Capital Limited Partnership increased its holdings in Pfizer by 43.4% during the second quarter. Arrowstreet Capital Limited Partnership now owns 18,718,955 shares of the biopharmaceutical company’s stock worth $453,747,000 after buying an additional 5,662,309 shares during the last quarter. Assenagon Asset Management S.A. lifted its stake in Pfizer by 75.0% in the third quarter. Assenagon Asset Management S.A. now owns 8,689,103 shares of the biopharmaceutical company’s stock valued at $221,398,000 after purchasing an additional 3,722,531 shares during the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its position in Pfizer by 84.9% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 7,561,946 shares of the biopharmaceutical company’s stock worth $183,302,000 after purchasing an additional 3,472,240 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

NYSE PFE opened at $26.66 on Friday. The company has a 50-day moving average price of $25.95 and a 200-day moving average price of $25.31. The firm has a market capitalization of $151.55 billion, a P/E ratio of 19.60 and a beta of 0.47. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.94. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.25%. The company had revenue of $17.56 billion for the quarter, compared to analysts’ expectations of $16.93 billion. During the same quarter last year, the business earned $0.63 EPS. The firm’s revenue was down 1.2% compared to the same quarter last year. Equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.5%. Pfizer’s dividend payout ratio (DPR) is 126.47%.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Erste Group nudged up its FY2026 and FY2027 EPS estimates (to $2.97 and $2.84 respectively), a modest improvement to street forecasts that supports earnings visibility. Erste Group estimate lift
• Positive Sentiment: Pfizer announced positive results from its BREAKWATER trial — a near-term pipeline win that can underpin future revenue and investor confidence if it advances toward approval/commercialization. Pfizer BREAKWATER trial results
• Positive Sentiment: Several bullish retail-focused pieces highlight Pfizer’s ~6% dividend yield, stable cash flows and defensive profile as reasons it could be a value/dividend play during market volatility. Those narratives support demand from income-focused investors. Massive News: Pfizer’s 6% Dividend Could Be Safer Than You Think
• Neutral Sentiment: Comparisons with AstraZeneca highlight that Pfizer trades cheaper and pays a higher yield, but AZN’s stronger growth targets temper PFE’s relative upside — useful context for allocation decisions. AstraZeneca vs. Pfizer
• Neutral Sentiment: Lists of high-dividend, low-volatility stocks include Pfizer, reinforcing its role as a defensive, income-oriented holding for some portfolios. 10 High Dividend Stocks With Low Volatility
• Negative Sentiment: Barclays initiated coverage with an underweight call, signaling fresh sell-side skepticism that can pressure the stock if other firms follow suit. Barclays initiates coverage with underweight
• Negative Sentiment: Critical commentaries warn that Pfizer’s ~6% yield carries risks (cash-flow pressure, payout sustainability, and valuation traps), fueling investor caution on dividend reliability. Pfizer: A Risky 6.3% Yield
• Negative Sentiment: Other analyst initiations noted in the press include bearish starts, adding to near-term sentiment pressure for the stock. Bearish analyst initiations

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. TD Cowen reissued a “hold” rating on shares of Pfizer in a report on Tuesday, December 30th. BMO Capital Markets reiterated an “outperform” rating on shares of Pfizer in a report on Wednesday, December 10th. The Goldman Sachs Group restated a “neutral” rating and set a $26.00 price target on shares of Pfizer in a research report on Wednesday, November 5th. Zacks Research downgraded shares of Pfizer from a “hold” rating to a “strong sell” rating in a research note on Monday, January 26th. Finally, Scotiabank started coverage on Pfizer in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, thirteen have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $27.84.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.